CN103649094B - 晶态的(1r,4r)‑6’‑氟‑N,N‑二甲基‑4‑苯基‑4’,9’‑二氢‑3’H‑螺[环己烷‑1,1’‑吡喃并[3,4,b]吲哚]‑4‑胺 - Google Patents

晶态的(1r,4r)‑6’‑氟‑N,N‑二甲基‑4‑苯基‑4’,9’‑二氢‑3’H‑螺[环己烷‑1,1’‑吡喃并[3,4,b]吲哚]‑4‑胺 Download PDF

Info

Publication number
CN103649094B
CN103649094B CN201280032432.XA CN201280032432A CN103649094B CN 103649094 B CN103649094 B CN 103649094B CN 201280032432 A CN201280032432 A CN 201280032432A CN 103649094 B CN103649094 B CN 103649094B
Authority
CN
China
Prior art keywords
dimethyl
fluoro
spiro
dihydro
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280032432.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN103649094A (zh
Inventor
M.格鲁斯
S.克卢格
S.普吕斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Parker Therapeutics
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Priority to CN201710173425.6A priority Critical patent/CN106939005A/zh
Publication of CN103649094A publication Critical patent/CN103649094A/zh
Application granted granted Critical
Publication of CN103649094B publication Critical patent/CN103649094B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
CN201280032432.XA 2011-07-08 2012-07-06 晶态的(1r,4r)‑6’‑氟‑N,N‑二甲基‑4‑苯基‑4’,9’‑二氢‑3’H‑螺[环己烷‑1,1’‑吡喃并[3,4,b]吲哚]‑4‑胺 Active CN103649094B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710173425.6A CN106939005A (zh) 2011-07-08 2012-07-06 晶态的（1r,4r）‑6’‑氟‑N,N‑二甲基‑4‑苯基‑4’,9’‑二氢‑3’H‑螺[环己烷‑1,1’‑吡喃并[3,4,b]吲哚]‑4‑胺

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11005587.8 2011-07-08
EP11005587 2011-07-08
PCT/EP2012/002839 WO2013007361A1 (en) 2011-07-08 2012-07-06 Crystalline (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710173425.6A Division CN106939005A (zh) 2011-07-08 2012-07-06 晶态的（1r,4r）‑6’‑氟‑N,N‑二甲基‑4‑苯基‑4’,9’‑二氢‑3’H‑螺[环己烷‑1,1’‑吡喃并[3,4,b]吲哚]‑4‑胺

Publications (2)

Publication Number Publication Date
CN103649094A CN103649094A (zh) 2014-03-19
CN103649094B true CN103649094B (zh) 2017-05-24

Family

ID=46717800

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280032432.XA Active CN103649094B (zh) 2011-07-08 2012-07-06 晶态的(1r,4r)‑6’‑氟‑N,N‑二甲基‑4‑苯基‑4’,9’‑二氢‑3’H‑螺[环己烷‑1,1’‑吡喃并[3,4,b]吲哚]‑4‑胺
CN201710173425.6A Pending CN106939005A (zh) 2011-07-08 2012-07-06 晶态的（1r,4r）‑6’‑氟‑N,N‑二甲基‑4‑苯基‑4’,9’‑二氢‑3’H‑螺[环己烷‑1,1’‑吡喃并[3,4,b]吲哚]‑4‑胺

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710173425.6A Pending CN106939005A (zh) 2011-07-08 2012-07-06 晶态的（1r,4r）‑6’‑氟‑N,N‑二甲基‑4‑苯基‑4’,9’‑二氢‑3’H‑螺[环己烷‑1,1’‑吡喃并[3,4,b]吲哚]‑4‑胺

Country Status (23)

Country Link
US (2) US8618156B2 (enExample)
EP (2) EP3235821B1 (enExample)
JP (2) JP6276689B2 (enExample)
CN (2) CN103649094B (enExample)
AR (1) AR087081A1 (enExample)
AU (2) AU2012283449B2 (enExample)
BR (1) BR112014000358A2 (enExample)
CA (1) CA2841032C (enExample)
CY (1) CY1120525T1 (enExample)
DK (2) DK2729470T3 (enExample)
EA (1) EA026750B1 (enExample)
ES (1) ES2641299T3 (enExample)
HR (1) HRP20170968T1 (enExample)
HU (1) HUE033043T2 (enExample)
IL (1) IL230331B (enExample)
LT (1) LT2729470T (enExample)
MX (1) MX2014000297A (enExample)
PL (1) PL2729470T3 (enExample)
PT (1) PT2729470T (enExample)
RS (1) RS56343B1 (enExample)
SI (1) SI2729470T1 (enExample)
TW (1) TWI585092B (enExample)
WO (1) WO2013007361A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2729470T3 (en) * 2011-07-08 2017-09-11 Gruenenthal Gmbh Crystalline (1r, 4r) -6'-fluoro-n, n-dimethyl-4-phenyl-4 ', 9'-dihydro-3'h-spiro [cyclohexane-1,1'-pyran [3,4, b ] indole] -4-amine
US10022353B2 (en) * 2015-01-23 2018-07-17 Grünenthal GmbH Cebranopadol for treating pain in subjects with impaired hepatic and/or impaired renal function
ES2713960T3 (es) 2015-02-02 2019-05-24 Ratiopharm Gmbh Composición que comprende cebranopadol en forma disuelta
JP7373904B2 (ja) 2016-02-29 2023-11-06 パーク・セラピューティクス・インコーポレイテッド セブラノパドールの滴定
CN112313202A (zh) * 2019-05-21 2021-02-02 江苏众强药业有限公司 曲前列尼尔钠盐新晶型及制备方法
CN112254496A (zh) * 2020-09-25 2021-01-22 榆林学院 一种煤泥收集装置
WO2024129782A1 (en) 2022-12-12 2024-06-20 Park Therapeutics, Inc. Regimens and compositions useful for alleviating pain
KR20250145673A (ko) 2023-02-15 2025-10-13 애드뉴리스 테라퓨틱스 인코포레이티드 통증 완화에 유용한 요법 및 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1735619A (zh) * 2002-11-11 2006-02-15 格吕伦塔尔有限公司 螺环环己烷衍生物
WO2006108565A1 (de) * 2005-04-11 2006-10-19 Grünenthal GmbH Spirocyclishe cyclohexanderivate zur behandlung von substanzabhängigkeit
CN101516844A (zh) * 2006-07-18 2009-08-26 格吕伦塔尔有限公司 具有对阿片样受体体系的活性的4-杂芳基取代的1-氨基环己烷-1-和环己烯-1-衍生物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006046745A1 (de) 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
AU2011287955B2 (en) * 2010-08-04 2015-07-09 Grünenthal GmbH Pharmaceutical dosage form comprising 6'-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
DK2729470T3 (en) * 2011-07-08 2017-09-11 Gruenenthal Gmbh Crystalline (1r, 4r) -6'-fluoro-n, n-dimethyl-4-phenyl-4 ', 9'-dihydro-3'h-spiro [cyclohexane-1,1'-pyran [3,4, b ] indole] -4-amine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1735619A (zh) * 2002-11-11 2006-02-15 格吕伦塔尔有限公司 螺环环己烷衍生物
WO2006108565A1 (de) * 2005-04-11 2006-10-19 Grünenthal GmbH Spirocyclishe cyclohexanderivate zur behandlung von substanzabhängigkeit
CN101516844A (zh) * 2006-07-18 2009-08-26 格吕伦塔尔有限公司 具有对阿片样受体体系的活性的4-杂芳基取代的1-氨基环己烷-1-和环己烯-1-衍生物

Also Published As

Publication number Publication date
BR112014000358A2 (pt) 2017-01-10
AU2012283449A1 (en) 2014-02-20
AR087081A1 (es) 2014-02-12
EP2729470A1 (en) 2014-05-14
WO2013007361A1 (en) 2013-01-17
EA026750B1 (ru) 2017-05-31
PT2729470T (pt) 2017-10-02
TW201311694A (zh) 2013-03-16
AU2012283449B2 (en) 2017-04-06
EP3235821B1 (en) 2020-04-08
US8765800B2 (en) 2014-07-01
CA2841032C (en) 2020-12-15
AU2017204572B2 (en) 2018-05-24
EP3235821A1 (en) 2017-10-25
IL230331B (en) 2018-11-29
RS56343B1 (sr) 2017-12-29
JP2014518226A (ja) 2014-07-28
ES2641299T3 (es) 2017-11-08
CY1120525T1 (el) 2019-07-10
JP2017081981A (ja) 2017-05-18
SI2729470T1 (sl) 2017-10-30
EP2729470B1 (en) 2017-06-21
TWI585092B (zh) 2017-06-01
DK2729470T3 (en) 2017-09-11
WO2013007361A8 (en) 2013-04-04
JP6276689B2 (ja) 2018-02-07
CN106939005A (zh) 2017-07-11
MX2014000297A (es) 2014-01-31
US20130231381A1 (en) 2013-09-05
US20130012563A1 (en) 2013-01-10
EA201400120A1 (ru) 2014-06-30
JP6559165B2 (ja) 2019-08-14
CN103649094A (zh) 2014-03-19
PL2729470T3 (pl) 2017-11-30
AU2017204572A1 (en) 2017-07-27
US8618156B2 (en) 2013-12-31
WO2013007361A9 (en) 2013-12-27
DK3235821T3 (da) 2020-04-20
HRP20170968T1 (hr) 2017-09-22
CA2841032A1 (en) 2013-01-17
AU2012283449A8 (en) 2014-03-27
HUE033043T2 (hu) 2017-11-28
LT2729470T (lt) 2017-08-25

Similar Documents

Publication Publication Date Title
CN103649094B (zh) 晶态的(1r,4r)‑6’‑氟‑N,N‑二甲基‑4‑苯基‑4’,9’‑二氢‑3’H‑螺[环己烷‑1,1’‑吡喃并[3,4,b]吲哚]‑4‑胺
US8614245B2 (en) Crystalline (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine
CN104105699B (zh) (1r,4r)-6’-氟-N,N-二甲基-4-苯基-4’,9’-二氢-3’H-螺[环己烷-1,1’-吡喃并[3,4,b]吲哚]-4-胺盐酸盐的固体形式
CN104114560B (zh) (1r,4r)-6’-氟-(N,N-二甲基)-4-苯基-4’,9’-二氢-3’H-螺[环己烷-1,1’-吡喃并[3,4,b]吲哚]-4-胺与硫酸的固体形式
HK1195900A (en) Crystalline (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
HK1195900B (en) Crystalline (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20221011

Address after: new jersey

Patentee after: Parker Therapeutics

Address before: Ah Xing, Germany

Patentee before: GRuNENTHAL GmbH

TR01 Transfer of patent right